Pancreatic ductal adenocarcinoma, PDAC, the main neoplastic disease of the pancreas (90% of cases), is a malignant tumour with a typically negative outcome and, indeed, it is the fourth cause of cancer death in the world, despite being the twelfth most common cancer in terms of incidence. The 5-year survival rate is below 8% and this aggressiveness is related to the rapid development without specific symptoms, the absence of screening tests, the consequent late diagnosis (85% of patients show metastases when the disease is discovered), and the inefficiency of current therapies, with just 10% of patients operable at the time of diagnosis.